Business


Goldman Sachs Group, Inc. (The) Reiterates "Sell" Rating for Barclays PLC (BARC)

About 485,694 shares traded. TG Therapeutics Inc (NASDAQ:TGTX) has risen 60.54% since June 20, 2016 and is uptrending. It has underperformed by 33.21% the S&P500. It has a 25.6 P/E ratio. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.


Three Americans Still Held by North Korea

Three Americans Still Held by North Korea

President Trump called the death of Otto Warmbier , American student freed from North Korea, a "disgrace", Tuesday. The President proceeded to say that Mr Warmbier's untimely death recommitted his administration to make sure that another tragedy like the one that surrounded Mr Warmbier would not happen again.



London fire death toll rises to 79

At least 70 people, including children and entire families, have been reported missing following the Grenfell Tower fire . He said it had been "incredibly emotional working in there", adding: "On Saturday I went in myself and went to the top floor".


Toshiba prefers US-Japan bidder for memory chip biz sale

Toshiba prefers US-Japan bidder for memory chip biz sale

Last week, Western Digital , which has invested in and jointly operates a flash memory plant with Toshiba in central Japan , said it asked a USA court to block Toshiba from selling the chip unit. It added that Toshiba's management favours the Broadcom-led deal, but the Japan-US-Korea consortium's automatic government stamp of approval means it is also in a strong position.



Technicals In Focus For Creative Edge Nutrition Inc (FITX) Shares

Peel Hunt reissued a "buy" rating and issued a GBX 1,330 ($16.82) price target on shares of Euromoney Institutional Investor PLC in a research note on Thursday, May 18th. They now have a GBX 172.00 target on the firm. Finally, Peel Hunt increased their price target on Mitie Group PLC from GBX 166 ($2.11) to GBX 175 ($2.23) and gave the company a "sell" rating in a research report on Wednesday, March 1st.